Breast cancer (BC) is one of the most common malignancies among women in the world. There is a global attempt to diagnose BC as early as possible. Long noncoding RNAs (lncRNAs) are emerging as novel targets and biomarkers for BC diagnosis and prognosis. Aberrant expression of lncRNAs is associated with BC development, making them a potential tumor marker for BC. To investigate this possibility, we determined the expression levels of Down syndrome cell adhesion molecule-antisense RNA-1 (DSCAM-AS1) and mitotically-associated long non-coding RNA (MANCR) lncRNAs in BC tissues. This case–control study included 50 paired tumor and adjacent nontumor tissues from female BC patients. The total RNA was isolated and the expression levels of MANCR and DSCAM-AS1 lncRNAs were assessed using quantitative real-time reverse transcription-PCR. Potential correlations between lncRNA levels and clinicopathological characteristics were also analyzed. DSCAM-AS1 and MANCR lncRNAs were significantly upregulated in BC tumor tissues compared with the adjacent nontumor tissues. We also found the significant upregulation of DSCAM-AS1 in advanced tumor–node–metastasis stage (TNM III) of BC tumor tissues. Furthermore, the expression of DSCAM-AS1 and MANCR in HER-2 positive patients was significantly higher than HER-2 negative affected individuals. Receiver operating characteristic curve analysis showed a satisfactory diagnostic efficacy (P value < 0.0001), which means that DSCAM-AS1 and MANCR lncRNAs can potentially serve as a biomarker. The present study might provide further approval for the clinical diagnostic significance of DSCAM-AS1 and MANCR lncRNAs that their high expressions were associated with aggressive clinical parameters of BC.

中文翻译：

---

长链非编码 RNA DSCAM-AS1 和 MANCR 的上调是乳腺癌的潜在诊断标志物

乳腺癌（BC）是世界上女性最常见的恶性肿瘤之一。全球都在尝试尽早诊断 BC。长链非编码 RNA (lncRNA) 正在成为 BC 诊断和预后的新靶点和生物标志物。lncRNA 的异常表达与 BC 的发展有关，使其成为 BC 的潜在肿瘤标志物。为了研究这种可能性，我们确定了 BC 组织中唐氏综合征细胞粘附分子反义 RNA-1 (DSCAM-AS1) 和有丝分裂相关长链非编码 RNA (MANCR) lncRNA 的表达水平。该病例对照研究包括来自女性 BC 患者的 50 对肿瘤和邻近的非肿瘤组织。分离总 RNA，并使用定量实时逆转录-PCR 评估 MANCR 和 DSCAM-AS1 lncRNA 的表达水平。还分析了 lncRNA 水平与临床病理学特征之间的潜在相关性。与邻近的非肿瘤组织相比，BC 肿瘤组织中的 DSCAM-AS1 和 MANCR lncRNA 显着上调。我们还发现 DSCAM-AS1 在 BC 肿瘤组织的晚期肿瘤 - 淋巴结 - 转移期（TNM III）中显着上调。此外，在 HER-2 阳性患者中 DSCAM-AS1 和 MANCR 的表达明显高于 HER-2 阴性患者。受试者工作特征曲线分析显示出令人满意的诊断效果（我们还发现 DSCAM-AS1 在 BC 肿瘤组织的晚期肿瘤 - 淋巴结 - 转移期（TNM III）中显着上调。此外，在 HER-2 阳性患者中 DSCAM-AS1 和 MANCR 的表达明显高于 HER-2 阴性患者。受试者工作特征曲线分析显示出令人满意的诊断效果（我们还发现 DSCAM-AS1 在 BC 肿瘤组织的晚期肿瘤 - 淋巴结 - 转移期（TNM III）中显着上调。此外，在 HER-2 阳性患者中 DSCAM-AS1 和 MANCR 的表达明显高于 HER-2 阴性患者。受试者工作特征曲线分析显示出令人满意的诊断效果（P值 < 0.0001），这意味着 DSCAM-AS1 和 MANCR lncRNA 可以作为生物标志物。本研究可能进一步证实 DSCAM-AS1 和 MANCR lncRNA 的临床诊断意义，即它们的高表达与 BC 的侵袭性临床参数相关。